Positive Neoadjuvant Libtayo® (cemiplimab) Monotherapy Data in Resectable Cutaneous ...

Retrieved on: 2022-09-13 07:55:05

Tags for this article:

Lung cancer

Cemiplimab

Sanofi

Regeneron Pharmaceuticals

Squamous cell carcinoma

Regeneron Pharmaceuticals Inc.

Click the tags to see associated articles and topics

Positive Neoadjuvant Libtayo® (cemiplimab) Monotherapy Data in Resectable Cutaneous .... View article details on HISWAI: https://pipelinereview.com/index.php/2022091381599/Antibodies/Positive-Neoadjuvant-Libtayo-cemiplimab-Monotherapy-Data-in-Resectable-Cutaneous-Squamous-Cell-Carcinoma-Presented-at-ESMO-and-Published-in-NEJM.html

Excerpt

Details: Category: Antibodies: Published on Tuesday, 13 September 2022 09:52 ... Libtayo is a fully human monoclonal antibody targeting the immune ...

Article found on: pipelinereview.com

View Original Article